Some cancer patients can find it hard to tell family and friends about their diagnosis: ‘You’re dealing with this all alone’
Ever since Anthony Bridges found out he had prostate cancer six years ago, he hasn’t stopped talking about it. He told his Facebook friends immediately. Now, the 68-year-old man from Georgia spends time working with others to encourage other men to talk to their doctor about getting screened. Not…#anthonybridges #georgia #defense #lloydaustin #wales #princewilliam #otisbrawley #bigc #bobdole #bettyford (Source: Reuters: Health)
Source: Reuters: Health - March 28, 2024 Category: Consumer Health News Source Type: news

Accuray touts data presented at Radiosurgery Society Meeting
Accuray is touting data presented at the 2024 Radiosurgery Society (RSS) meeting in Chicago, which the company said supports the use of the CyberKnife System in treating high-risk and recurrent prostate cancer. CyberKnife allows for treatment of prostate cancer using stereotactic body radiation therapy (SBRT), where high doses of radiation are delivered over a shorter duration than traditional treatments. The company said that CyberKnife offers a treatment option for prostate tumors in four to five sessions. Data presented at the meeting suggested that at three years follow-up, the system achieved favorable biochemical c...
Source: AuntMinnie.com Headlines - March 26, 2024 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Source Type: news

The rise of theranostics: Part 1 -- Gaining momentum
Since the U.S. Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research.Theranostics pairs diagnostic biomarkers that can be visualized on nuclear medicine imaging with therapeutic agents that share a specific target in diseased cells or tissues. After the therapeutic agent binds to the cancer cells, the tumors are treated in such a way that aims to prevent collateral damage to healthy cells and improve overall outcomes.Theranostics isn’t new; nuclear medicine d...
Source: AuntMinnie.com Headlines - March 26, 2024 Category: Radiology Authors: Liz Carey Tags: Practice Management Molecular Imaging Radiation Oncology/Therapy Nuclear Medicine Source Type: news

MRI-Guided TULSA Effective at Five Years for Localized Prostate Cancer
MONDAY, March 25, 2024 -- For the treatment of localized prostate cancer, in-bore, magnetic resonance imaging (MRI)-guided transurethral ultrasound ablation (TULSA) results in favorable outcomes at five years, including durable oncologic control and... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 25, 2024 Category: Pharmaceuticals Source Type: news

Helping Poorer Patients Pay for Prostate Cancer Meds Keeps Them on Treatment
MONDAY, March 25, 2024— Men with prostate cancer treated at hospitals participating in a special drug-pricing program were more likely to stick to their therapy than patients elsewhere, new research reveals. The federal 340B Drug Program... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 25, 2024 Category: General Medicine Source Type: news

RSNA calls out toxicity concerns with theranostics
While recent evidence suggests that theranostic agents may be more effective when used earlier for prostate cancer patients, experts recommend proceeding conservatively with theranostic treatments until more is known about dose limits, according to an article published March 21 by the RSNA. Data from theranostics is starting to focus on radiation dosimetry and dose limits in relation to kidney and other organ damage, said Nadine Mallak, MD, associate professor of body imaging and nuclear medicine at Oregon Health and Science University in Portland. The article points out that compared with external beam radiation therapy...
Source: AuntMinnie.com Headlines - March 22, 2024 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Nuclear Radiology Source Type: news

MRI/ultrasound combination effective for treating prostate cancer
A new, minimally invasive procedure that combines MRI and transurethral ultrasound is effective for treating prostate cancer, according to research presented March 20 at the Society of Interventional Radiology (SIR) meeting in Salt Lake City. A team led by Steven Raman, MD, of the David Geffen School of Medicine at the University of California, Los Angeles, found that the treatment -- dubbed MRI-guided transurethral ultrasound ablation (TULSA) and performed by interventional radiologists -- proved a viable alternative to surgery or radiation, showing a recovered continence rate of 92% at five-year follow-up. "This image-...
Source: AuntMinnie.com Headlines - March 21, 2024 Category: Radiology Authors: Kate Madden Yee Tags: Interventional MRI Ultrasound Genitourinary Radiology Source Type: news

Mutation Linked to Increased Risk of Prostate Cancer Mortality
(MedPage Today) -- The risk of dying of prostate cancer doubled in the presence of a genetic mutation affecting testosterone production, a large prospective cohort study showed. The 5-year risk of prostate cancer-specific mortality (PCSM) increased... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 20, 2024 Category: Hematology Source Type: news

Ultrasound Plus MRI Could Be New Treatment Strategy Against Prostate Cancer
WEDNESDAY, March 20, 2024 -- Precisely delivered ultrasound could be an effective treatment for prostate cancer, with high-frequency sound waves heating and killing off cancer cells, a new study says. The treatment killed off all prostate cancer... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 20, 2024 Category: General Medicine Source Type: news

AstraZeneca to buy fusion for $2 billion
​​The deal gives AstraZeneca a foothold in the radiopharmaceutical drugs market, which has seen increasing investor interest since 2021 when data from Novartis' treatment showed that the drug extended survival for prostate cancer patients. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 19, 2024 Category: Pharmaceuticals Source Type: news

Up to 20,000 prostate cancer diagnoses could have been missed during the pandemic, research suggests
Analysis of 24million patient records since 2020 found tens of thousands of men have missed potentially life-saving cancer diagnoses. (Stock Image general view of hospital ward.) (Source: the Mail online | Health)
Source: the Mail online | Health - March 17, 2024 Category: Consumer Health News Source Type: news

Nearly 20,000 Prostate Cancer Diagnoses Missed In England Because Of Covid-19 Pandemic
The Covid-19 pandemic has led to delays in diagnosing prostate cancer that in turn can significantly affect odds of survival and treatment options. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - March 17, 2024 Category: Pharmaceuticals Authors: Bruce Y. Lee, Senior Contributor Tags: Healthcare /healthcare Innovation /innovation Science /science business pharma standard Source Type: news

Targeted radiopharmaceuticals offer new hope for longer'healthspans '
Mark Crockett, MD, chief medical officer at TeleDaaS.Americans today can expect to live long lives. However, increased longevity has brought on a troubling rise in chronic disease, diminishing the quality of life later in life. A 2018 study from the U.S. Centers for Disease Control and Prevention (CDC) found that more than a quarter of U.S. adults now battle multiple chronic conditions, up from 22% in 2001. We may be living longer, but more Americans struggle through these extra years in poor health — presenting a pressing need to extend not just lifespans but “healthspans.” An emerging field of precision radiopharm...
Source: AuntMinnie.com Headlines - March 15, 2024 Category: Radiology Tags: Molecular Imaging Source Type: news

Clarity reports on third cohort in copper theranostic trial
Clarity Pharmaceuticals has completed its third cohort in the theranostic SECuRE trial evaluating copper-64 (Cu-64) and copper-67 (Cu-67) sarcophagine chelator technology in patients with metastatic castration-resistant prostate cancer. In this phase I/IIa trial of Cu-64 for the diagnostic and Cu-67 for the therapeutic, the company noted no dose-limiting toxicities in cohort 3, and an overall safety review of all cohorts 1, 2, and 3 also showed favorable safety profiles. Cohort 3 participants had the highest number of pretreatments prior to entering the study across all cohorts, with most patients receiving five or more l...
Source: AuntMinnie.com Headlines - March 15, 2024 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Nuclear Radiology Radiation Oncology Source Type: news

Black Men Face Highest Incidence of Prostate Cancer in the U.K.
THURSDAY, March 14, 2024 -- Among primary care patients in the United Kingdom, the incidence of prostate cancer with an elevated prostate-specific antigen (PSA) result is higher among Black men than White or Asian men, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 14, 2024 Category: Pharmaceuticals Source Type: news